email article
Not every cancer drug approved by the FDA receives approval and coverage in England and Canada, two studies in
JAMA Internal Medicine showed.
In England, a retrospective cohort study looked at 68 drugs given accelerated approval by the FDA from December 1992 to May 2017 that also received market approval in the European Union. The researchers, Elias Mossialos, MD, PhD, of the London School of Economics and Political Science, and colleagues, found that only 45 drug indications (66.2%) were recommended for public coverage through the National Health Services (NHS), and that 39 of the 45 (86.7%) were recommended only after price negotiation or collection of further data to verify the clinical benefit.
The most frequently mutated gene in human cancers is called p53. Patients with Li-Fraumeni syndrome, which is a rare disorder that increases the risk of developing several types of cancer, often have an increased risk to develop cancers at early ages if they inherit p53 mutations.